Compare IDEXX Laboratories, Inc. (IDXX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Banco Santander SA — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 4.8× IDEXX Laboratories, Inc.'s market cap, and Banco Santander SA pays a 2.06% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Banco Santander SA for 55 Days on average.
| IDXX | SAN | |
|---|---|---|
Market Cap | $40.43B | $192.86B |
Volume | 692,164 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $766.68 | $15.05 |
52-Week Low | $504.70 | $9.65 |
Typical Hold Time | 46 Days | 55 Days |
Enterprise Value | $41.32B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Banco Santander (SAN) trades at $13.48, down 1.32% with bearish technical signals despite strong fundamentals. The stock shows mixed earnings performance with Q1 2026 beat but Q2 miss, while maintaining robust profitability with 26.25% net margin and 16.07% ROE. Recent developments include the completed Webster Financial acquisition expanding U.S. presence and record quarterly profits reported in Q2 2026.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), though negative cash flow trends and declining operating cash flow from $56.7B in 2021 to -$24.2B in 2024 raise concerns. The Webster integration execution and European banking sector volatility represent key near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
